Study of Everolimus in de Novo Renal Transplant Recipients
Status:
Terminated
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
In the present study, the investigators propose a conversion scheme with 50% reduction in CNI
dosage until adjustment of everolimus dosage, in order to reach a trough blood level of 6-10
ng/mL, thus avoiding overimmunosuppression or alternatively breakthrough rejection episodes.
The hypothesis of this study is to demonstrate that the therapeutic regimen with Myfortic®
and Certican® significantly improves renal function compared with the standard regimen of
CNI.